LISATA THERAPEUTICS, INC. — Director's Dealing 2017

Apr 27, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2017-04-25

Reporting Person: Mazzo David J (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-04-25	Common Stock	F	690	$4.74	Disposed	74329	Direct

Footnotes

F1: Includes 36,785 shares of unvested restricted stock.